Web27 gen 2013 · ASG-5ME is a Novel Antibody-Drug Conjugate in Evaluation for the Treatment of Pancreatic, Gastric and Prostate Cancers. BOTHELL, WA, USA I January 25, 2013 I Seattle Genetics, Inc. (SGEN) today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal … Web1 feb 2013 · Background: ASG-5ME is an antibody-drug conjugate (ADC) targeting SLC44A4, an ion transporter expressed on >90% of pancreatic ductal adenocarcinoma …
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody
WebSi tratta di uno studio clinico di fase 1, in aperto, con aumento della dose per sottovalutare la sicurezza e tollerabilità di ASG-5ME e identificare la dose massima tollerata nei pazienti … WebUno studio per la dose massima tollerata di ASG-5ME in soggetti con cancro alla prostata resistente alla castrazione Uno studio di fase 1, in aperto, multicentrico, sull'aumento … cineworld solihull showings
Phase I trial of ASG-5ME in metastatic castration-resistant prostate ...
Web%PDF-1.6 %âãÏÓ 9 0 obj /Filter/Adobe.PPKLite/M(D:20121025134753-05'00')/Name(ARE Production V6.1 P17 0007609)/Prop_Build >/Filter >/PubSec >>>/Reference[>/Type ... Web6 feb 2024 · ASG-5ME, an SLC44A4-targeting antibody carrying monomethyl auristatin E (MMAE), a microtubule-disrupting agent, was investigated in men with metastatic castration resistant prostate cancer. Methods The primary objective of this phase I study was to determine maximum tolerated dose (MTD) and recommended phase II dose. Web20 mag 2012 · ASG-5ME is an antibody drug conjugate (ADC) comprised of a fully human antibody targeting SLC44A4, conjugated to the microtubule-disrupting agent monomethyl … cineworld south ruislip address